Toxina Botulínica na paralisia do Nervo Facial
Revisão Sistemática
DOI:
https://doi.org/10.35699/2178-1990.2026.62136Palavras-chave:
toxinas botulínicas, paralisia facial, nervo facial, neurotoxinasResumo
Objetivo: este estudo avaliou a eficácia e segurança do uso da toxina botulínica no manejo de sequelas funcionais e estéticas da paralisia facial periférica.
Métodos: esta revisão sistemática foi conduzida nas bases PubMed, Lilacs e CENTRAL, incluindo estudos clínicos e observacionais. A avaliação do viés na qualidade metodológica foi baseada nos critérios da American Society of Plastic Surgeons.
Resultados: esta revisão considerou 25 publicações. Os estudos incluíram pacientes entre 16 e 75 anos, tratados com toxina botulínica isolada ou combinada a outras terapias. Resultados demonstraram melhora significativa na simetria facial, redução de sincinesias e ganhos funcionais, com taxas médias de eficácia superiores a 70%. A satisfação dos pacientes foi elevada em mais de 90% dos casos, e os eventos adversos foram leves, autolimitados e transitórios.
Conclusão: a toxina botulínica representa uma intervenção eficaz, segura e bem tolerada no manejo da paralisia facial periférica, sobretudo quando associada a estratégias multimodais de reabilitação. Ainda assim, há necessidade de estudos para padronização de protocolos e fortalecimento das recomendações clínicas.
Referências
Dall’Angelo A, Mandrini S, Sala V, Pavese C, Carlisi E, Comelli M, et al. Platysma synkinesis in facial palsy and botulinum toxin type A. Laryngoscope. 2014;124(11):2513-2517.
Filipo R, Spahiu I, Covelli E, Nicastri M, Bertoli GA. Botulinum toxin in the treatment of facial synkinesis and hyperkinesis. Laryngoscope. 2012;122(2):266-270.
de Carvalho VF, Vieira APS, Paggiaro AO, Salles AG, Gemperli R. Evaluation of the body image of patients with facial palsy before and after the application of botulinum toxin. Int J Dermatol. 2019;58(10):1175-1183.
Wei, EX, Green, A, Pepper, JP, Akkina, SR. Increasing incidence of facial nerve disorders in the United States from 2007 to 2022. Laryngoscope. 2025;135(6) 2008-2013.
Valença MM, Valença LPAA, Lima MCM. Paralisia facial periférica idiopática de Bell: a propósito de 180 pacientes. Arq Neuropsiquiatr. 2001;59(3B):733-739.
Lee JM, Choi KH, Lim BW, Kim MW, Kim J. Half-mirror biofeedback exercise in combination with three botulinum toxin A injections for long-lasting treatment of facial sequelae after facial paralysis. J Plast Reconstr Aesthet Surg. 2015;68(1):71-78.
D’Andrea FP, Alessi C, Cárcano C, Tanaka V, Alvares B, Brito D, et al. Evaluation of the efficacy of the combined therapy of botulinum toxin and hyaluronic acid compared to conservative intervention in the treatment of chronic peripheral facial paralysis of oncologic etiology. Aesthetic Plast Surg. 2025;49(11):2861-2870.
Akulov MA, Tanyashin S V., Shimansky VN, Usachev DY, Orlova OR, Zakharov VO, et al. The efficacy of botulinum therapy in treatment of delayed facial palsy after resection of vestibular schwannoma. Zh Vopr Neirokhir Im N N Burdenko. 2018;82(5):81-87.
Kim J. Contralateral botulinum toxin injection to improve facial asymmetry after acute facial paralysis. Otology Neurotol. 2013;34(2):319-324.
Hernández Herrero D, Abdel Muti García E, López Araujo J, Alfonso Barrera E, Moraleda Pérez S. Cost of peripheral facial palsy treatment with botulinum toxin type A. J Plast Reconstr Aesthet Surg. 2022;75(1):271-277.
Akulov MA, Orlova OR, Orlova AS, Usachev DJ, Shimansky VN, Tanjashin SV, et al. IncobotulinumtoxinA treatment of facial nerve palsy after neurosurgery. J Neurol Sci. 2017;381:130-134.
Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg. 2011;128(1):305-310.
Lacroix G, Duquennoy-Martinot V, Guerreschi P. Le musque buccinateur: une nouvelle cible pour les injections de toxine botulique dans le traitement des sequelaes de paralysie faciale. Ann. Chir. Plast. Esthet. 2022;67(3) :125-132.
Cecini M, Pavese C, Comelli M, Carlisi E, Sala V, Bejor M, et al. Quantitative measurement of evolution of postparetic ocular synkinesis treated with botulinum toxin type a. Plast Reconstr Surg. 2013;132(5):1255-1264.
Remigio AFDN, Salles AG, de Faria JCM, Ferreira MC. Comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA at the 1:3 conversion ratio for the treatment of asymmetry after long-term facial paralysis. Plast Reconstr Surg. 2015;135(1):239-249.
Mandrini S, Comelli M, Dall’angelo A, Togni R, Cecini M, Pavese C, et al. Long-term facial improvement after repeated BoNT-A injections and mirror biofeedback exercises for chronic facial synkinesis: a case-series study. Eur J Phys Rehabil Med. 2016;52(6):810-818.
Patel PN, Owen SR, Norton CP, Emerson BT, Bronaugh AB, Ries WR, et al. Outcomes of buccinator treatment with botulinum toxin in facial synkinesis. JAMA Facial Plast Surg. 2018;20(3):196-201.
Orlova OR, Akulov MA, Usachev DI, Taniashin SV, Zakharov VO, Saksonova E V, et al. The use of botulinum toxin type a in the acute phase of facial nerve injury after neurosurgical surgery. Zh Vopr Neirokhir Im N N Burdenko. 2014;78(6):50-54.
Pourmomeny AA, Pourali E, Chitsaz A. Neuromuscular retraining versus BTX-A injection in subjects with chronic facial nerve palsy, a clinical trial. Iran J Otorhinolaryngol. 2021;33(116):151-155.
Monini S, De Carlo A, Biagini M, Buffoni A, Volpini L, Lazzarino AI, et al. Combined protocol for treatment of secondary effects from facial nerve palsy. Acta Otolaryngol. 2011;131(8):882-886.
Moraleda S, Hachoue Z, Abdel-Muti E, Ruiz G, Díez Sebastián J, Lassaletta L. Satisfaction survey of patients with sequels of peripheral facial palsy treated with botulinum toxin A. Rehabilitacion (Madr). 2020;54(4):254-259.
Salles AG, Toledo PN, Ferreira MC. Botulinum toxin injection in long-standing facial paralysis patients: improvement of facial symmetry observed up to 6 months. Aesthetic Plast Surg. 2009;33(4):582-590.
Mehta RP, Hadlock TA. Botulinum toxin and quality of life in patients with facial paralysis. Arch Facial Plast Surg. 2008;2(10):84-87.
McElhinny ER, Reich I, Burt B, Mancini R, Wladis EJ, Durairaj VD, et al. Treatment of pseudoptosis secondary to aberrant regeneration of the facial nerve with botulinum toxin type A. Ophthalmic Plast Reconstr Surg. 2013;29(3):175-178.
Neville C, Venables V, Aslet M, Nduka C, Kannan R. An objective assessment of botulinum toxin type A injection in the treatment of post-facial palsy synkinesis and hyperkinesis using the synkinesis assessment questionnaire. J Plast Reconstr Aesthet Surg. 2017;70(11):1624-1628.
Salles AG, Mota WM, Remigio AFDN, de Andrade ACH, Gemperli R. Management of post-facelift facial paralysis with botulinum toxin type A. Aesthet Surg J. 2022;42(3):NP144-NP150.
Toffola ED, Furini F, Redaelli C, Prestifilippo E, Bejor M. Evaluation and treatment of synkinesis with botulinum toxin following facial nerve palsy. Disabil Rehabil. 2010;32(17):1414-1418.
Sadiq SA, Khwaja S, Saeed SR. Botulinum toxin to improve lower facial symmetry in facial nerve palsy. Eye (Lond). 2012;26(11):1431-1436.
Toledo PN. Efeito da terapia miofuncional em pacientes com paralisia facial de longa duração associada à aplicação de toxina botulínica [tese]. São Paulo(SP): Faculdade de Medicina da Universidade de São Paulo; 2007.
Wehrlin C, Picard D, Tankéré F, Hervochon R, Foirest C. Pain in patients with post paralytic hemifacial spasm: before, during and after botulinum toxin injections. Toxins (Basel). 2022;14(1):20.
Caribé CL. Toxina botulínica do tipo A para assimetria relacionada à paralisia facial [dissertação]. Brasília(DF): Universidade de Brasília; 2023.
Chen CK, Tang YB. Myectomy and botulinum toxin for paralysis of the marginal mandibular branch of the facial nerve: a series of 76 cases. Plast Reconstr Surg. 2007;120(7):1859-1864.
Winterhoff J, Laskawi R. Anwendung von botulinumtoxin beim blepharospasmus, spasmus facialis und bei synkinesien nach fazialisdefektheilung. HNO. 2012;60(6):479-483.
Bulstrode NW, Harrison DH. The phenomenon of the late recovered Bell’s palsy: treatment options to improve facial symmetry. Plast Reconstr Surg. 2005;115(6):1466-1471.
